GERN

Geron Corporation develops and commercializes RYTELO (imetelstat), a therapeutic treatment for lower-risk myelodysplastic syndromes with transfusion-dependent anemia. Geron is pursuing regulatory approvals and commercialization in the U.S. and European Union, along with efforts to expand RYTELO to additional patient populations and indications. Geron faces typical biotech risks including clinical trial enrollment, regulatory approval timelines, and manufacturing challenges.

Pipeline

Catalyst Calendar